Optogenetic and Chemogenetic Dissection of Cell Transplants
Optogenetic and Chemogenetic Dissection of Cell Transplants
批准号:
10617567
负责人:
THYAGARAJAN SUBRAMANIAN
金额:
$36.12万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-05-04 至 2024-04-30
关键词:
AgonistAllograftingAmericanAntiparkinson AgentsAxonBackBasal GangliaBehaviorBehavior assessmentBehavioralBiochemicalCell LineCell NucleusCell TransplantationCellsChloridesClinicalClinical TrialsClozapineCorpus striatum structureDataDeep Brain StimulationDiseaseDissectionDopamineDopamine ReceptorDopaminergic CellDoseDrug-Induced DyskinesiaElectroencephalographyElectrophysiology (science)EnsureEuropeExhibitsFemaleFunctional disorderFutureGTP-Binding ProteinsGenesGrantHalorhodopsinsHigh Pressure Liquid ChromatographyHigh PrevalenceHistologyHumanImplantInflammatory ResponseInternal Ribosome Entry SiteLasersLesionLettersLevodopaLiftingLightLoxP-flanked alleleMediatingMethodsMicrodialysisMicroelectrodesModelingMonkeysMorbidity - disease rateMotorMotor CortexMuscarinic Acetylcholine ReceptorNeuronsOperative Surgical ProceduresOpsinOxidopamineParkinson DiseaseParkinsonian DisordersPatientsPatternPhototoxicityProteinsRattusRegulationReproducibilityResearchResolutionRoleSafetySubstantia nigra structureSymptomsSynapsesSynaptic ReceptorsSystemTechniquesTestingTherapeuticTimeTransplantationUnited States National Institutes of Healthawakebehavioral studyclinical investigationclinical translationconnectomedesigner receptors exclusively activated by designer drugsdisabilitydopaminergic neuronexperimental studyfetalgraft functionhistological studiesimprovedin vivoinclusion criteriamalemedical complicationneurochemistryneurophysiologynovel therapeuticsoptogeneticsparkinsonian rodentpars compactareceptorrecombinant viral vectorreuptakeside effectstem cellsvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Parkinson's disease (PD) causes disability in an estimated 1 million Americans and is characterized by
progressive loss of dopaminergic neurons that originate in the substantia nigra pars compacta (SNpc) and their
axons. Levodopa (LD) in some form is required to control symptoms of PD in vast majority of patients, but its
use causes drug-induced dyskinesias (DID), motor and non motor fluctuations, disabling complications that
remains a major problem in contemporary management of PD. Intermittent high dose LD treatments, loss of
continuous dopaminergic stimulation (CDS) along with dopamine receptor super sensitivity are hypothesized
as causative factors for DID and fluctuations. It is also well accepted that information transfer from the motor
cortex to the basal ganglia and back is abnormal in PD and correction of electrophysiological abnormalities
may be critical to provide symptomatic relief to patients with advanced PD. Our studies show that the
electrophysiological changes that occur in the basal ganglia as result of parkinsonism remain largely
unmitigated with round the clock LD treatments despite excellent amelioration of parkinsonian behavior. In
contrast, dopaminergic cell transplants into the striatum “normalize” basal ganglia neurophysiology and
parkinsonian behavioral abnormalities. We show that synaptic connectivity between the graft and the host is
critical and necessary to mediate these effects. These findings suggest that pre-synaptic factors such as the
presence of nigrostriatal synapses that enables focused release of dopamine, its reuptake and regulation via
pre-synaptic receptors may all be important to minimize the motor complications of PD. Recent studies have
shown that dopaminergic cell transplantation for PD can be successful and without deleterious side effects
providing >2 decades of effective anti-parkinsonian benefits to patients. This has led to the lifting of the
moratorium on clinical cell transplantation for PD. However, optimization of cell transplantation techniques
including the ability to externally control the functioning of the grafts and its newly formed synaptic connections
with the host is critical to ensure safety of future clinical translation of such grafts. Therefore, we seek to
comprehensively evaluate the hypothesis that electrophysiological “normalization” in the basal ganglia –
cortical circuit is necessary to mitigate or eliminate DID and fluctuations in PD. Using a highly reproducible rat
model of PD that exhibit DID and fluctuations, optogenetic and chemogenetic modulation of grafts such that
they can be turned “off” and “on”, awake basal ganglia single cell recordings, LFP recordings, EEG and in vivo
microdialysis combined with HPLC-Ms/Ms we plan to study the biochemical and electrical abnormalities in the
basal ganglia and the cortex associated with DID and fluctuations in PD. Multiple nuclei in the basal ganglia
and its known connections will be probed. Extensive histological studies will also be performed. This research
will provide mechanistic basis for the electrophysiological abnormalities that accompany DID, motor and non-
motor fluctuations in PD and help discover methods to correct them.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Optogenetic and Chemogenetic Dissection of Cell Transplants
-
批准号:10160983
-
项目类别:
-
资助金额:$35.19万
-
财政年份:2018
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
A LONGITUDINAL OBSERVATIONAL FOLLOW-UP OF THE PRECEPT STUDY COHORT (POSTCEPT)
-
批准号:7951265
-
项目类别:
-
资助金额:$0.37万
-
财政年份:2009
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
DRUG COMBINATION FOR PARKINSON'S DISEASE
-
批准号:7951270
-
项目类别:
-
资助金额:$0.28万
-
财政年份:2009
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
PROTOCOL #191622-057
-
批准号:7951269
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2009
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
A LONGITUDINAL OBSERVATIONAL FOLLOW-UP OF THE PRECEPT STUDY COHORT (POSTCEPT)
-
批准号:7625801
-
项目类别:
-
资助金额:$0.18万
-
财政年份:2007
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
ASNTR Annual Meeting Student Travel Awards
-
批准号:7278066
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2007
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Mucana Pruriens for dyskinesias in Parkinson's disease
-
批准号:6870829
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2005
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Mucana Pruriens for dyskinesias in Parkinson's disease
-
批准号:7216097
-
项目类别:
-
资助金额:$18.31万
-
财政年份:2005
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral Transplantation in Parkinsonian Monkeys
-
批准号:6406135
-
项目类别:
-
资助金额:$33.08万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral Transplantation in Parkinsonian Monkeys
-
批准号:6540522
-
项目类别:
-
资助金额:$34.36万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral Transplantation in Parkinsonian Monkeys
-
批准号:6721339
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral transplantation in Parkinsonian Monkeys
-
批准号:7033543
-
项目类别:
-
资助金额:$37.78万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral transplantation in Parkinsonian Monkeys
-
批准号:7871974
-
项目类别:
-
资助金额:$7.76万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral Transplantation in Parkinsonian Monkeys
-
批准号:6639820
-
项目类别:
-
资助金额:$33.3万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral transplantation in Parkinsonian Monkeys
-
批准号:7569966
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral transplantation in Parkinsonian Monkeys
-
批准号:7364132
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral transplantation in Parkinsonian Monkeys
-
批准号:7195694
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral transplantation in Parkinsonian Monkeys
-
批准号:7777248
-
项目类别:
-
资助金额:$35.21万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
Intranigral Transplantation in Parkinsonian Monkeys
-
批准号:6501354
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2001
-
负责人:THYAGARAJAN SUBRAMANIAN
-
依托单位:
海外基金